Navigation Links
Soligenix Announces Pricing of Public Offering of Common Stock and Warrants
Date:6/21/2013

PRINCETON, N.J., June 21, 2013 /PRNewswire/ -- Soligenix, Inc. (OTCQB: SNGX) ("Soligenix" or the "Company"), a clinical stage biopharmaceutical company focused on developing products to treat inflammatory diseases and biodefense countermeasures where there remains an unmet medical need, announced today the pricing of a registered public offering of shares of common stock and warrants to purchase common stock.

In connection with the public offering, the Company has entered into definitive agreements with institutional investors and certain members of the Company's management and Board of Directors to sell approximately $7.0 million of the Company's securities, consisting of an aggregate of approximately 6.6 million shares of common stock at a price per share of $1.05 and 5-year warrants to purchase up to approximately 5.0 million shares of common stock with an exercise price of $1.65 per share.

Institutional investors in the offering include, among others, an affiliated fund of Third Security, LLC ("Third Security"), a venture capital firm founded by R.J. Kirk.  In connection with Third Security's investment in the Company, the Company intends to appoint a Third Security designee to the Board of Soligenix.

The Company plans to use the net proceeds from the offering to further develop its product candidates and for general working capital purposes.

Soligenix's two lead product candidates include a proprietary formulation of oral BDP (beclomethasone 17,21-dipropionate) for pediatric Crohn's disease (SGX203), which is currently in a Phase 1 clinical trial, and a novel innate defense regulator (IDR) technology for the treatment of oral Mucositis (SGX942) for which the Company plans to initiate a Phase 2 clinical trial in the second half of 2013.

Maxim Group LLC served as placement agent for the offering.

The securities described above were offered
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Grants Soligenix "Fast Track" Designation for SGX942 for the Treatment of Oral Mucositis in Patients with Head and Neck Cancer
2. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
3. Soligenix Reports First Quarter 2013 Financial Results and Highlights Recent Accomplishments
4. Soligenix and Intrexon Pursue Melioidosis Therapy Through Worldwide Exclusive Collaboration
5. Soligenix to Present at World Vaccine Congress & Expo
6. Soligenix Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate SGX942 for the Treatment of Oral Mucositis
7. Soligenix to Present at 15th Annual BIO CEO & Investor Conference
8. Soligenix Announces Formation of Oral Mucositis Medical Advisory Board
9. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
10. Soligenix Reports Third Quarter 2012 Financial Results and Highlights Recent Accomplishments
11. FDA Grants Soligenix Fast Track Designation for SGX203 for the Treatment of Pediatric Crohns Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... -- Semler Scientific, Inc. (Nasdaq: SMLR ), an ... markets products that assist healthcare providers in monitoring patients ... the first quarter ended March 31, 2015. ... continued progress with year over year growth of 44% ... said Doug Murphy-Chutorian , M.D., chief executive officer ...
(Date:5/1/2015)... May 1, 2015  AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... E. Morris , chief financial officer  will be participating ... are as follows: Mizuho Third Annual Healthcare ... Omni Berkshire Place, New York ...
(Date:5/1/2015)... YORK , May 1, 2015  Shares of ... 70% of their value yesterday following the results of ... glaucoma therapy, Rhopressa.  Despite the trial failing to meet ... that positive results may come from future studies. ... brief company overview, current pipeline, financial review, analyst summary, ...
Breaking Medicine Technology:Semler Reports First Quarter 2015 Financial Results 2Semler Reports First Quarter 2015 Financial Results 3Semler Reports First Quarter 2015 Financial Results 4Semler Reports First Quarter 2015 Financial Results 5AcelRx Pharmaceuticals to Participate at Upcoming Investor Conferences in May 2All is Not Lost for Aerie Pharmaceuticals - VLM Research Issued by BrokerBank Securities, Inc. 2
... DIEGO, Oct. 20 Aethlon Medical, Inc. (OTC Bulletin ... the Aethlon Hemopurifier® is effective in capturing the current ... Hemopurifier® is the first-in-class medical device able to selectively ... During invitro studies, the Hemopurifier® removed ...
... , WALTHAM, Mass., Oct. 20 Logical Therapeutics, Inc. ... treat medical conditions associated with inflammation, has been selected ... the gastrointestinal (GI) safety of its lead product LT-NS001, ... Annual Scientific Meeting on October 27, 2009. , ...
Cached Medicine Technology:Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 2Aethlon Medical Releases Medical Device Data Against the H1N1 Swine Flu Virus 3Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting 2
(Date:5/3/2015)... May 03, 2015 AvePoint, ... across platforms and devices, today announced it is ... Privacy Professionals (IAPP) Asia Privacy Forum, taking place ... Throughout the event, AvePoint will showcase its compliance, ... cloud platforms. , Visit AvePoint for New Solutions ...
(Date:5/3/2015)... 2015 Barbara Crone has joined Women’s Excellence ... being of the men, women and families who seek her care, ... care for families in the home. , “When ... wondering if I could complete their care with the delivery of ... my mentor Nurse Midwife, I knew it was time for me ...
(Date:5/3/2015)... Metamora, Michigan (PRWEB) May 03, 2015 ... mark on their Facebook page. , Their ... on the many services the Practice has, it’s multiple ... events. , Women’s Excellence has a very strong social ... Pinterest, Instagram and You Tube. , Women’s Excellence ...
(Date:5/3/2015)... Association 2015 Meeting & Tradeshow (PRWEB) May 03, ... full-service telemedicine and mobile health services provider today ... health services for chronic disease management, in the ... remote patient monitoring of a variety of chronic ... diabetes, COPD, hypertension and other chronic illnesses. , ...
(Date:5/3/2015)... Leading international program provider, Child ... awarding the 2015 Harris Wofford Global Service Fellowships. CFHI ... the deserving recipients of the award named after former ... Wofford. The two recipients were chosen for their strong ... , CFHI is one of seven organizations participating ...
Breaking Medicine News(10 mins):Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 2Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 3Health News:AvePoint Showcases Compliance and Data Privacy Solutions as Platinum Sponsor of IAPP Asia Privacy Forum 2015 4Health News:Women's Excellence In Midwifery Welcomes Barbara Crone 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 2Health News:vitaphone e-health solutions U.S. Announces VITA Health Services for Remote Chronic Disease Management 3Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 2Health News:SF-based Global Health Non-Profit Awards Harris Wofford Global Service Fellowship 3
... At ... about profitable new strategies, especially in the areas of financing and operations, that they can ... ... sponsored by Horst Construction will be held from 8:30 a.m. to 2 p.m. on Thursday, ...
... 2010 Of the 200,000 men newly diagnosed with ... one-third will undergo surgical treatment. Although open radical prostatectomy ... prostatectomy (LRP) with or without robotic assistance is becoming ... today in The Journal of Urology , researchers ...
... ATLANTA--A new study has found that many male cancer ... radiation therapy have an impaired quality of life and ... , a peer-reviewed journal of the American Cancer Society, ... testosterone deficiency may benefit from testosterone replacement therapy. ...
... are being denied access to adequate pain relief because ... opioid-based drugs such as morphine. Authors ... pain-killing drugs in this way is a breach of ... an ethical and public health imperative to address these ...
... ... ... ... ...
... ... service, Thibadeau Mortuary opens it newest location in beautiful Olde Towne Gaithersburg Maryland. ... serve today,s creative and multicultural community. , ... Gaithersburg, MD (PRWEB) February 21, 2010 -- A new, affordable ...
Cached Medicine News:Health News:Register Online for this Year's Horst Senior Living Conference on April 8 Featuring Keynote Speaker and Senior Housing Expert Jim Moore 2Health News:Few differences in outcomes between open and laparoscopic prostate surgery 2Health News:Inadequate access to opioid-based pain relief is a human rights issue for cancer patients 2Health News:Inadequate access to opioid-based pain relief is a human rights issue for cancer patients 3Health News:Inadequate access to opioid-based pain relief is a human rights issue for cancer patients 4Health News:Live with Regis and Kelly Reveal A REVOLUTIONARY Pain Relief Method 2Health News:Live with Regis and Kelly Reveal A REVOLUTIONARY Pain Relief Method 3Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 2Health News:Olde Towne Gaithersburg Welcomes Thibadeau Mortuary - A Lower-Cost Alternative In Funeral and Cremation Service 3
For use with catalog #0454....
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies....
Detection of Lupus Anticoagulants. Freeze-dried hexagonal phase phos-phatidylethanolamine; normal plasmawith heparin inhibitor; PTT-LS reagent of cephalin and particulate siliceous activator;all free...
Antigenic Total Protein S, ELISA Method...
Medicine Products: